PSYBF (PsyBio Therapeutics) ROC %: -241.07% (As of Jun. 2023)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is PsyBio Therapeutics ROC %?

PsyBio Therapeutics PSYBF -90.00% ROC % is -241.07% as of Jun. 2023.

ROC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROIC %. PsyBio Therapeutics's annualized return on capital (ROC %) for the quarter that ended in Jun. 2023 was -241.07%.

As of today (2026-07-15), PsyBio Therapeutics's WACC % is 0.00%. PsyBio Therapeutics's ROC % is 0.00% (calculated using TTM income statement data). PsyBio Therapeutics earns returns that do not match up to its cost of capital. It will destroy value as it grows.

PsyBio Therapeutics  (OTCPK:PSYBF) ROC % Explanation

ROC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROIC %. The reason book values of debt and equity are used is because the book values are the capital the company received when issuing the debt or receiving the equity investments.

There are four key components to this definition. The first is the use of operating income or EBIT rather than net income in the numerator. The second is the tax adjustment to this operating income or EBIT, computed as a hypothetical tax based on an effective or marginal tax rate. The third is the use of book values for invested capital, rather than market values. The final is the timing difference; the capital invested is from the end of the prior year whereas the operating income or EBIT is the current year's number.

Why is ROC % important?

Because it costs money to raise capital. A firm that generates higher returns on investment than it costs the company to raise the capital needed for that investment is earning excess returns. A firm that expects to continue generating positive excess returns on new investments in the future will see its value increase as growth increases, whereas a firm that earns returns that do not match up to its cost of capital will destroy value as it grows.

As of today, PsyBio Therapeutics's WACC % is 0.00%. PsyBio Therapeutics's ROC % is 0.00% (calculated using TTM income statement data). PsyBio Therapeutics earns returns that do not match up to its cost of capital. It will destroy value as it grows.

Be Aware

Like ROE % and ROA %, ROC % is calculated with only 12 months of data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

PsyBio Therapeutics ROC % Related Terms

PsyBio Therapeutics ROC % Historical Data

* Premium members only.

The historical data trend for PsyBio Therapeutics's ROC % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

PsyBio Therapeutics ROC % Chart

PsyBio Therapeutics Annual Data
Trend Dec21 Dec22
ROC %
-74,369.23 -3,181.27

PsyBio Therapeutics Quarterly Data
Dec19 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23
ROC % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1,156.48 -845.71 -1,090.07 -1,294.55 -241.07

PsyBio Therapeutics ROC % Calculation

PsyBio Therapeutics's annualized Return on Capital (ROC %) for the fiscal year that ended in Dec. 2022 is calculated as:

ROC % (A: Dec. 2022 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (A: Dec. 2021 ) + Invested Capital (A: Dec. 2022 ))/ count )
=-4.756 * ( 1 - 0% )/( (0.013 + 0.286)/ 2 )
=-4.756/0.1495
=-3,181.27 %

where

Invested Capital(A: Dec. 2021 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=4.008 - 0.941 - ( 3.805 - max(0, 0.941 - 3.995+3.805))
=0.013

Invested Capital(A: Dec. 2022 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=0.39 - 1.782 - ( 0.001 - max(0, 1.931 - 0.253+0.001))
=0.286

PsyBio Therapeutics's annualized Return on Capital (ROC %) for the quarter that ended in Jun. 2023 is calculated as:

ROC % (Q: Jun. 2023 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Mar. 2023 ) + Invested Capital (Q: Jun. 2023 ))/ count )
=-0.628 * ( 1 - 0% )/( (0.209 + 0.312)/ 2 )
=-0.628/0.2605
=-241.07 %

where

Invested Capital(Q: Mar. 2023 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=0.3 - 1.822 - ( 0.069 - max(0, 1.932 - 0.201+0.069))
=0.209

Invested Capital(Q: Jun. 2023 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=0.283 - 1.836 - ( 0.012 - max(0, 1.971 - 0.106+0.012))
=0.312

Note: The Operating Income data used here is four times the quarterly (Jun. 2023) data. The tax rate is limited to between 0% and 100%.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROC % →
What does a ROC % of -241.07% mean?
PsyBio Therapeutics (PSYBF) has a ROC % of -241.07% as of Jun. 2023. Return on capital is the ratio of current-period net income to average two-period capital. View historical data on PsyBio Therapeutics and its competitors.
Is PsyBio Therapeutics' ROC % too high?
PsyBio Therapeutics' current ROC % is -241.07%.
How does PsyBio Therapeutics' ROC % compare to VRTX and REGN?
PsyBio Therapeutics' ROC % of -241.07% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROC % for a Biotechnology company?
A good ROC % depends on the Biotechnology industry context. However, ROC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROC % mean?
A high ROC % can signal that a stock is expensive relative to its fundamentals. Return on capital is the ratio of current-period net income to average two-period capital. View historical data on PsyBio Therapeutics and its competitors. PsyBio Therapeutics's current ROC % is -241.07%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PsyBio Therapeutics stock overvalued right now?
PsyBio Therapeutics (PSYBF) has a current ROC % of -241.07%. The current ROC % is -241.07%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROC % calculated?
ROC % is calculated from a company's financial statements. For PsyBio Therapeutics (PSYBF), the current ROC % is -241.07% as of Jun. 2023. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

PsyBio Therapeutics Business Description

Address 1624 Washington Street, Denver, CO, USA, 80203
PsyBio Therapeutics Corp is a biotechnology company. The company is engaged in the development of drugs intended for the treatment of mental illness and neurological disorders.